 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Euforvac (DTwP-HepB) / LG Chem, Hexasiil (DTwP–HepB-IPV-Hib) / Serum Institute of India
Journal: A phase I, open label, clinical study to assess the safety and immunogenicity of indigenously developed liquid (DTwP-HepB-IPV-Hib) hexavalent combination vaccine in healthy toddlers aged 16-24 months. (Pubmed Central) - Nov 23, 2022
was found to be safe, well tolerated and showed a robust immune response in toddlers. It was concluded that this vaccine should be assessed in the next phases of clinical development in the target population.Clinical Trial Registration - CTRI/2018/10/015875.